首页 | 本学科首页   官方微博 | 高级检索  
检索        


Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes
Authors:Martino Rodrigo  Iacobelli Simona  Brand Ronald  Jansen Thekla  van Biezen Anja  Finke Jürgen  Bacigalupo Andrea  Beelen Dietrich  Reiffers Jossy  Devergie Agnes  Alessandrino Emilie  Mufti Ghulam J  Barge Renée  Sierra Jorge  Ruutu Tapani  Boogaerts Marc  Falda Michele  Jouet Jean-Pierre  Niederwieser Dieter  de Witte Theo;Myelodysplastic Syndrome subcommittee of the Chronic Leukemia Working Party of the European Blood and Marrow Transplantation Group
Institution:Division of Clinical Hematology, Hopital de la Sant Creu i Sant Pau, Autonomous University of Barcelona, Spain. rmartino@santpau.es
Abstract:In this multicenter retrospective study, the outcomes of 836 patients with myelodysplastic syndrome (MDS) who underwent transplantation with a human leukocyte antigen (HLA)-identical sibling donor were analyzed according to 2 types of conditioning: reduced-intensity conditioning (RIC) in 215 patients, and standard myeloablative (or high-dose) conditioning (SMC) in 621 patients. In multivariate analysis, the 3-year relapse rate was significantly increased after RIC (hazard ratio HR], 1.64; 95% confidence interval 95% CI], 1.2-2.2; P = .001), but the 3-year nonrelapse mortality (NRM) rate was decreased in the RIC group (HR, 0.61; 95% CI, 0.41-0.91; P = .015). The 3-year probabilities of progression-free and overall survivals were similar in both groups (39% after SMC vs 33% in RIC; multivariate P = .9; and 45% vs 41%, respectively; P = .8). In conclusion, the lower 3-year NRM after RIC is encouraging, since these patients were older (age > 50 years in 73% RIC vs 28% in SMC, P < .001) and had more adverse pretransplantation variables. However, based on the higher risk of relapse, patients with no contraindications for SMC should not receive RIC outside of prospective randomized trials, which are needed to establish the position of RIC-based transplantation in the treatment of patients with MDS.
Keywords:
本文献已被 PubMed 等数据库收录!
点击此处可从《Blood》浏览原始摘要信息
点击此处可从《Blood》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号